Last reviewed · How we verify

ropivicaine 0.2%

University of Alabama at Birmingham · FDA-approved active Small molecule

Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Local and regional anesthesia for surgical procedures, Peripheral nerve blocks, Epidural anesthesia.

At a glance

Generic nameropivicaine 0.2%
Also known asNaropin
SponsorUniversity of Alabama at Birmingham
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Ropivacaine reversibly binds to and blocks voltage-gated sodium channels on the inner surface of nerve cell membranes, preventing sodium influx and thus inhibiting depolarization. This action blocks the generation and conduction of nerve impulses in a dose-dependent manner, producing local anesthesia. It is an amide-type local anesthetic with a lower propensity for cardiotoxicity compared to bupivacaine.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: